[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2017/08/Smartwatch-runner.jpg” thumb_width=”150″ /]A new Innovate UK challenge
has opened for digital health technology developers. They are seeking subject matter experts (SME) to lead a group in designing digital health innovations which achieve at least one of these objectives: improving patient outcomes, transforming healthcare delivery, and enabling more efficient delivery of healthcare. Total funding is £35m. It appears that each winner will be granted up to £8m as follows: feasibility–£50,000 to £75,000; industrial research and experimental development–£500,000 to £1 million.
This follows on our previously reported £12m Biomedical Catalyst program [TTA 5 Apr]. Innovate UK’s digital health program is being funded by the Industrial Strategy Challenge Fund which is also backing battery power and robotics challenge programs.
Detailed information and application information may be found here. Applications close Wednesday 11 October 2017 at noon. Hat tip to Tynetec via Twitter. (Illustration from Innovate UK and innovation leader Chris Sawyer’s blog.)
[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2017/04/Entra.jpg” thumb_width=”150″ /]Entra is a London startup company developing a quick, home-based blood test for clinically valid blood counts. Targeted to the needs of chemotherapy patients, where blood counts are critical in their receiving and timing of treatments, the Affinity (photo left) is designed to take a small sample, analyze it, wirelessly send the information to the hospital or clinic, and enter into the patient’s EHR. It is currently being tested with The Royal Marsden Hospital, a leading UK cancer center, to validate its optical analytics and generate cost-effectiveness data. Blood counts are not only critical to correct patient treatment, but also to assigning and canceling appointments. Entra is being supported by £1.14 million in funding from Innovate UK, much of it through the Biomedical Catalyst. The timeline to commercial release is being estimated at two years. It’s anticipated that once verified, the blood count technology could be further developed for other uses. Gov.UK. Hat tip to our Eye on Tenders, Susanne Woodman
Raising funds for another type of blood testing is a NYC-based biotech company, Haystack, which is pioneering a single blood test for multiple cancers through proteome molecular profiling. Its goal is early detection of multiple cancers through one test using panels of biomarkers. The research team headed by John Wilson, PhD, who is affiliated with Cold Spring Harbor Laboratory, are ready first with pancreatic and lung cancer samples. This has gained the interest of pharma companies who are seeking a companion diagnostic for their drug trials. It was also a category winner at MedStartr’s #MedMo16 last December and presenter at #RISE2017 in March. Haystack’s MedStartr page. Video of Haystack’s presentation at #RISE2017 is on YouTube here (at 58:00) TTA is a MedStartr and Health 2.0 NYC supporter/media sponsor since 2010; event videos are available at Medstartr.tv.
The Innovate UK Biomedical Catalyst program now has a £12m challenge program for innovative projects in several healthcare areas, including:
- stratified healthcare (both therapy and diagnostic components)
- advanced therapies (cell and gene therapy)
- digital health
- enabling medical technologies and devices
The fund was established by Innovate UK, the Medical Research Council and Scottish Enterprise. Deadline for challenge registration is midday 31 May. A few more details: projects must be led by an SME either working alone or with others; projects can range in size from £250,000 to £4 million and to last between 12 and 36 months; businesses could attract up to 70 percent of their project costs. Innovate UK/Gov.UK page.
‘Fem-Tech’ is a new term to this Editor, but it perfectly describes Chiaro with its smart pelvic floor exercise tool and app, Elvie. It was originally grant-funded by Innovate UK, but has gained an additional £4.8 million from Octopus Ventures and Allbright for a total funding of £9.6 million. It is profitable with direct sales of £800,000, which is another proof that innovators ‘playing the niches’ in the current fragmented environment may be the smartest of all. Plans include building on current major retailers including John Lewis and Amazon, developing three more smart female health products and expand into 25 countries. Innovate UK/Gov.UK page Hat tip for both Innovate UK items to our Eye on Tenders, Susanne Woodman.
Fancy a startup in Barcelona? Look no further than the NUMA Barcelona Accelerator. Note entries needed by 25th September.
The Biomedical Catalyst 2016 early stage award competition requires registrations by 7th September, applications in by 14th September.
The European Commission has opened a public consultation on the safety of apps and other non-embedded software as part of an effort to ensure a high level of health, safety and consumer protection. Be sure to respond by closing date of 14th September.
Baker Botts, the international firm of lawyers specialising in intellectual property has very kindly agreed to continue to support the London Health Technology Forum which has now agreed three evening events this autumn, on 15th September, 20th October & 24th November. The programmes are (more…)